| ||
| ||
Why MAP Pharmaceutical Shares Popped Motley Fool What: Shares of development-stage drug company MAP Pharmaceutical (Nasdaq: MAPP ) jumped as high as 20% today, after its New Drug Application resubmission for Levadex was accepted by the FDA. So what: The FDA's ruling helps pave the way for ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment